MicroRNA and cutaneous melanoma: From discovery to prognosis and therapy

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1823-1832

  Segura, Miguel F ^a   Greenwald, Holly S ^a   Hanniford, Doug ^a   Osman, Iman ^a   Hernando, Eva ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPILIMUMAB; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 125B; MICRORNA 149; MICRORNA 155; MICRORNA 182; MICRORNA 205; MICRORNA 211; MICRORNA 214; MICRORNA 221; MICRORNA 222; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; MELANOCYTE; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MELANOMA; MICRORNAS; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867322248     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs205     Document Type: Article

References (107)

1. Bleyer, A. et al. (2006) Cancer in 15- to 29-year-olds by primary site. Oncologist, 11, 590-601.
2. Kohler, B.A. et al. (2011) Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl. Cancer Inst., 103, 714-736.
3. Lee, R.C. et al. (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-854.
4. Reinhart, B.J. et al. (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 403, 901-906.
5. Bernstein, E. et al. (2003) Dicer is essential for mouse development. Nat. Genet., 35, 215-217.
6. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
7. Zhang, L. et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U.S.A., 103, 9136-9141.
8. Bonazzi, V.F. et al. (2012) MicroRNA regulation of melanoma progression. Melanoma Res., 22, 101-113.
9. Flørenes, V.A. et al. (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin. Cancer Res., 6, 3614-3620.
10. Schultz, J. et al. (2008) MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res., 18, 549-557.
11. Müller, D.W. et al. (2008) Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene, 27, 6698-6706.
12. Johnson, S.M. et al. (2005) RAS is regulated by the let-7 microRNA family. Cell, 120, 635-647.
13. Chen, J. et al. (2011) miR-193b Regulates Mcl-1 in Melanoma. Am. J. Pathol., 179, 2162-2168.
14. Polsky, D. et al. (2003) Oncogenes in melanoma. Oncogene, 22, 3087-3091.
15. Noguchi, S. et al. (2012) Comparative Study of Anti-Oncogenic MicroRNA-145 in Canine and Human Malignant Melanoma. J Vet Med Sci.
16. Felicetti, F. et al. (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res., 68, 2745-2754.
17. Garofalo, M. et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 16, 498-509.
18. Igoucheva, O. et al. (2009) MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem. Biophys. Res. Commun., 379, 790-794.
19. Curtin, J.A. et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol., 24, 4340-4346.
20. Roberts, J.D. (2006) E2F1 amplication and genetic heterogeneity in melanoma. Cancer Biol. Ther., 5, 691-692.
21. Limon, J. et al. (1988) Chromosome changes in metastatic human melanoma. Cancer Genet. Cytogenet., 30, 201-211.
22. Dar, A.A. et al. (2011) miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem., 286, 16606-16614.
23. Xu, Y. et al. (2012) Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br. J. Cancer.
24. Amiri, K.I. et al. (2005) Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev., 24, 301-313.
25. Liu, S. et al. (2012) MicroRNA-9 up-regulates E-cadherin through inhibition of NF-KappaB1-Snail1 pathway in melanoma. J. Pathol., 226, 61-72.
26. Levati, L. et al. (2009) Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology, 35, 393-400.
27. Greenberg, E. et al. (2011) Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE, 6, e18936.
28. Chiang, A.C. et al. (2008) Molecular basis of metastasis. N. Engl. J. Med., 359, 2814-2823.
29. Fu, T.Y. et al. Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. Exp. Cell Res., 317, 445-451.
30. Li, X. et al. (1998) Differential expression of alphav integrins in K1735 melanoma cells. Invasion Metastasis, 18, 1-14.
31. Penna, E. et al. (2011) microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J., 30, 1990-2007.
32. Cruz, J. et al. (2003) Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology, 65, 72-82.
33. Otsuka, T. et al. (1998) c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res., 58, 5157-5167.
34. Taghizadeh, R. et al. (2010) CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS ONE, 5, e15183.
35. Migliore, C. et al. (2008) MicroRNAs impair MET-mediated invasive growth. Cancer Res., 68, 10128-10136.
36. Gaziel-Sovran, A. et al. (2011) miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 20, 104-118.
37. Janik, M.E. et al. (2010) Cell migration-the role of integrin glycosylation. Biochim. Biophys. Acta, 1800, 545-555.
38. Rambaruth, N.D. et al. (2011) Cell surface glycan-lectin interactions in tumor metastasis. Acta Histochem., 113, 591-600.
39. Elson-Schwab, I. et al. (2010) MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE, 5.
40. Mazar, J. et al. (2011) Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett., 585, 2467-2476.
41. Bell, R.E. et al. (2011) The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res., 24, 1088-1106.
42. Carreira, S. et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev., 20, 3426-3439.
43. Hoek, K.S. et al. (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res., 68, 650-656.
44. Bemis, L.T. et al. (2008) MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res., 68, 1362-1368.
45. Haflidadóttir, B.S. et al. (2010) miR-148 regulates Mitf in melanoma cells. PLoS ONE, 5, e11574.
46. Segura, M.F. et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. U.S.A., 106, 1814-1819.
47. Felicetti, F. et al. (2008) MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev. Anticancer Ther., 8, 1759-1765.
48. Hou, L. et al. (2000) Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development, 127, 5379-5389.
49. Phung, B. et al. (2011) C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS ONE, 6, e24064.
50. Mazar, J. et al. (2010) The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE, 5, e13779.
51. Levy, C. et al. (2010) Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol. Cell, 40, 841-849.
52. Boyle, G.M. et al. (2011) Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res., 24, 525-537.
53. Mueller, D.W. et al. (2011) MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int. J. Cancer, 129, 1064-1074.
54. Braig, S. et al. (2010) MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell. Mol. Life Sci., 67, 3535-3548.
55. Glud, M. et al. (2010) Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res., 20, 479-484.
56. Glud, M. et al. (2011) MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res., 21, 253-256.
57. Satzger, I. et al. (2010) MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. International journal of cancer. Journal international du cancer, 126, 2553-2562.
58. Streicher, K.L. et al. (2012) A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene.
59. Pan, X. et al. (2011) MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther., 10, 1224-1232.
60. Yang, C.H. et al. (2011) MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J. Biol. Chem., 286, 39172-39178.
61. Jiang, L. et al. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. Acta Histochem.
62. Jin, L. et al. (2011) MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 108, 15840-15845.
63. Kawakami, Y. et al. (2005) Immunological detection of altered signaling molecules involved in melanoma development. Cancer Metastasis Rev., 24, 357-366.
64. Márquez-Rodas, I. et al. (2011) A new era in the treatment of melanoma: from biology to clinical practice. Clin. Transl. Oncol., 13, 787-792.
65. Heinemann, A. et al. (2012) Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res., 72, 460-471.
66. Vinther, J. et al. (2006) Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res., 34, e107.
67. Chi, S.W. et al. (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature, 460, 479-486.
68. Hafner, M. et al. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell, 141, 129-141.
69. Godshalk, S.E. et al. (2011) A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene, 30, 1542-1550.
70. Rudolph, P. et al. (2000) Telomerase activity in melanocytic lesions: A potential marker of tumor biology. The American journal of pathology, 156, 1425-1432.
71. Polsky, D. et al. (2001) HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer research, 61, 7642-7646.
72. Hofmann, U.B. et al. (2000) Coexpression of integrin alpha(v)beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. The Journal of investigative dermatology, 115, 625-632.
73. Berger, A.J. et al. (2004) Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer research, 64, 8767-8772.
74. Gilad, S. et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS ONE, 3, e3148.
75. Mitchell, P.S. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A., 105, 10513-10518.
76. Valadi, H. et al. (2007) Exosome-mediated transfer of mRNAs and micro-RNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 9, 654-659.
77. Zomer, A. et al. (2010) Exosomes: Fit to deliver small RNA. Commun. Integr. Biol., 3, 447-450.
78. Resnick, K.E. et al. (2009) The detection of differentially expressed micro-RNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic oncology, 112, 55-59.
79. Chin, L.J. et al. (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res., 68, 8535-8540.
80. Chen, X. et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research, 18, 997-1006.
81. Miller, B.A. et al. (2008) Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control, 19, 227-256.
82. Fornari, F. et al. (2008) MiR-221 controls CDKN1C/p57 and CDKN1B/ p27 expression in human hepatocellular carcinoma. Oncogene, 27, 5651-5661.
83. Ciafrè,S.A. et al. (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun., 334, 1351-1358.
84. Kanemaru, H. et al. (2011) The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. Journal of dermatological science, 61, 187-193.
85. Chan, E. et al. (2011) MicroRNA signatures differentiate melanoma subtypes. Cell Cycle, 10, 1845-1852.
86. Poliseno, L et al. (2011) Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. Journal of Clinical Oncology, 29, (suppl; abstr 8540)
87. Leidinger, P. et al. (2010) High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer, 10, 262.
88. Xi, Y. et al. (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA, 13, 1668-1674.
89. Liu, A. et al. (2009) MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int. J. Clin. Exp. Pathol., 2, 519-527.
90. Glud, M. et al. (2009) MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J. Invest. Dermatol., 129, 1219-24.
91. Caramuta, S. et al. (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol., 130, 2062-70.
92. Segura, M.F. et al. (2010) Melanoma MicroRNA signature predicts post-recurrence survival. Clin. Cancer Res., 16, 1577-86.
93. Nguyen, T. et al. (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics: official journal of the DNA Methylation Society, 6, 388-94.
94. Rubin, K.M. et al. (2009) Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park), 23, 13-21.
95. Flaherty, K.T. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med., 363, 809-19.
96. O'Day, S. et al. (2011) A randomised, phase II study of intetumumab, an anti-av-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br. J. Cancer, 105, 346-52.
97. Johannessen, C.M. et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468, 968-72.
98. Nazarian, R. et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468, 973-7.
99. Tong, A.W. et al. (2008) Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther., 15, 341-55.
100. van Rooij, E. et al. (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 316, 575-9.
101. Elmén, J. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896-9.
102. Meister, G. et al. (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA, 10, 544-50.
103. Weiler, J. et al. (2006) Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther., 13, 496-502.
104. Davis, M.E. et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-70.
105. Huynh, C. et al. (2011) Efficient in vivo microRNA targeting of liver metastasis. Oncogene, 30, 1481-88.
106. Xu, S. et al. (2007) MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J. Biol. Chem., 282, 25053-66.
107. Schwimmer, J. et al. (2000) A review of the literature for whole-body FDG PET in the management of patients with melanoma. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine, 44, 153-67.